Search results
Sep 3, 2024 · PEP-Therapy welcomes Ursula Vogel to its Board of Directors. October 5th, 2021 PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors.
Feb 6, 2024 · PD Dr med. Ursula Vogl has been recently elected as president of the Project Group Urogenital Cancer. She is currently in charge as medical oncologist and group lead of urogenital cancers at the Department of Oncology at the Oncology Institute of Southern Switzerland (IOSI) and is the clinical head of the Prostate Cancer Center of Southern ...
In the next part of this session, Dr. Vogel, the medical oncologist, presented her perspective on how she believes this patient should be treated. The recently published CARD study 1 randomized 255 patients with mCRPC to either cabazitaxel or androgen signaling targeted inhibitors (abiraterone or enzalutamide).
La PD Dr.ssa med. Ursula Vogl è un'oncologa specializzata in tumore alla prostata presso EOC. Consulta il suo profilo per conoscere l'iter professionale, i contatti e le sedi di lavoro.
Biography. Senior consultant oncologist and responsible for genitourinary cancers at the Oncology Institute of Southern Oncology (IOSI). Clinical Lead of the Prostate Center of Southern Switzerland (CPSI). Researcher and co-investigator of several national and international studies.
Ursula VOGL, Attendant | Cited by 1,319 | | Read 37 publications | Contact Ursula VOGL
Ursula Vogl, MD, discusses her career in the prostate cancer and renal cell cancer fields, as well as recent projects that she has contributed to including a prostate cancer investigator-led trial on patients with PSA-only progression.
